All In Biotech

Drug Trial Radar · NCT00809965

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome

Last checked: Nov 19, 2026Latest source record: Sep 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 15,526 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

15,526

Actual

Start

Nov 2008

Primary completion

Sep 2011

Study completion Sep 2011

Sponsor

Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
Bayer
First posted
Dec 17, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary syndrome compared with placebo.

Conditions

  • Acute Coronary Syndrome
  • Myocardial Infarction
  • Myocardial Ischemia
  • Unstable Angina

Interventions

  • Rivaroxaban 2.5 mgDrug

    One tablet twice daily

  • Rivaroxaban 5 mgDrug

    One tablet twice daily

  • PlaceboDrug

    One placebo tablet twice daily

  • Standard of careDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Percentage of Patients With the Composite Endpoint of Cardiovascular Death, Myocardial Infarction, or StrokeTime frame: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)

Locations

556 sites in 43 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Geneva, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Anaheim, California

  • Site not named

    Burbank, California

  • Site not named

    Los Angeles, California

  • Site not named

    Mission Hills, California

  • Site not named

    San Diego, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Littleton, Colorado

  • Site not named

    Jacksonville, Florida

  • Site not named

    Jupiter, Florida

  • Site not named

    Kissimmee, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Ormond Beach, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Columbus, Georgia

  • Site not named

    Rome, Georgia

  • Site not named

    Aurora, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Merrillville, Indiana

  • Site not named

    Munster, Indiana

  • Site not named

    Valparaiso, Indiana

  • Site not named

    Overland Park, Kansas

  • Site not named

    Wichita, Kansas

  • Site not named

    Lacombe, Louisiana

  • Site not named

    Bethesda, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Flint, Michigan

  • Site not named

    Grand Blanc, Michigan

  • Site not named

    Grand Rapids, Michigan

  • Site not named

    Kalamazoo, Michigan

  • Site not named

    Mount Clemens, Michigan

  • Site not named

    Petoskey, Michigan

  • Site not named

    Tupelo, Mississippi

  • Site not named

    St Louis, Missouri

  • Site not named

    Kalispell, Montana

  • Site not named

    Bridgewater, New Jersey

Showing 40 of 556 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.